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The objective of the present study was to define the role o f chemotherapy, in the form  of the EP 
regimen, consisting o f epirubicin (E) and cisplatin (P) in addition to irradiation in com bination with 
5-fluorouracil (5-FU) for treatment of pancreatic cancer. 53 eligible patients with histologically or 
cytologically proven locally advanced pancreatic cancer were treated with three cycles o f  E 60 mg/m2 
(if this dose was well tolerated then the dose of E was increased by 10 mg/m2 in the next cycle; 80 mg/m2 
was the maximum dose for the following cycles) and P 100 mg/m2 once every 3 weeks, followed after 4 
weeks by a split course of irradiation of 40 Gy with 5-FU 500 mg/m2 on each o f the first 3 days of each 
20 Gy treatment segment. This was followed by another three cycles of EP in patients who achieved 
stable disease (SD) or a better response after the first three cycles. The treatment given with standard 
anti-emetics was moderately tolerated. The chemotherapy related toxicity consisted m ainly of myelo- 
suppression and the chemoradiotherapy related toxicity o f gastrointestinal side-effects. However, due 
to the long duration o f treatment which made the whole treatment difficult to endure, only 18/53 (34%) 
actually completed the full treatment regimen. Responses were evaluated after the first three cycles 
and 4 weeks after the completion o f the treatment by serial CT-scans using standard criteria* The 
results in 53 evaluable patients after the first three cycles of EP were as follows: 1 patient achieved a 
clinical complete response (CR), 7 a partial response (PR) (CR + PR: 15%; 95% confidence interval 
(Cl): 11-33%), 36 patients (68%) had stable disease (SD) and 6 patients progressive disease (PD ). There 
was 1 early P D , 1 toxic death and 1 patient could not be evaluated. The response at the end of the 
treatment was 3 CR, 11 PR (CR + PR: 14/53 (26%); 95% Cl: 15-40%), 30 SD and 6 PD . The m edian time 
to progression was 8.9 months and the median duration o f response 13.1 months. The m edian survival 
o f all treated patients was 10.8 months (range 7 days to 41.5 months), of responders 15.1 m onths and, 
o f the patients with SD 10.3 months. These results are comparable to other com bined modality 
regimens reported in the literature for locally advanced disease. The addition o f the system ic treatment 
with E and P  offers no additional advantage to combined modality treatment alone. Copyright © 1996 
Published by Elsevier Science Ltd
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INTRODUCTION
T he  i n c i d e n c e  of adenocarcinom a o f  the pancreas has steadily 
increased over the past four decades [1]. D espite trem endous 
efforts in early diagnosis and  therapy the prognosis is still
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dismal. T h e  percentage of surgically resectable patients is less 
than  2 0 %j and o f those resected the m edian  survival is only 
9 -15  m onths [23 3] while 5-year survival ra tes  are less than 
5% [4, 5].
Approximately 40% of patients with pancreatic  cancer pre­
sent w ith locally advanced disease [6]. T his stage has been 
defined as unresectable disease due to  regional lym ph node 
involvement and/or encasement of m ajor b lo o d  vessels, but
in n
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without evidence of hepatic or other distant métastasés. T o  be 
staged as locally advanced* it should be possible to encom pass 
the tu m o u r in a moderately sized upper gastrointestinal radi­
ation target volume. Currently accepted management involves 
the use of combined modality treatm ent with 5-fluor our a cil 
(5-FU) and radiation therapy [7].
C hem otherapy is poorly active [8], but previous studies 
from our E O R T C  group have reported an objective significant 
response after epirubicin treatm ent [9] and cisplatin adm inis­
tration [10].
T h e  objective of the  present study was to define the role o f 
chemotherapy* in the form o f the E P  regimen* consisting o f  
epirubicin (E) and cisplatin (P) in addition to irradiation in 
com bination with 5 -F U  for treatm ent of pancreatic cancer.
PATIENTS AND METHODS
All patients entered into this trial had histologically or 
cytologically proven ductal adenocarcinoma of the pancreas. 
Inclusion criteria included the following: inoperable disease 
due to  ingrowth in surrounding tissue or positive regional 
lymph nodes; no distant metastases on chest X-ray— anterio r- 
posterior and lateral— and on the C T-scan of the whole abdo­
men; age less than 71 years; W H O  performance status ^ 2 ;  
kidney and liver function tests normal; WBC ^ 4 x l 0 9/l* 
platelet count s i 00 x  109/1; all regional disease encompassed 
within a 400 cm 2 radiation therapy field. Informed consent 
was required. Criteria for exclusion were: prior chemotherapy 
or radiotherapy* active infection* brain or leptomeningeal 
disease* concom itant other malignant disease and overt car­
diac disease.
Statistical considerations
T h e  first endpoint analysed was response to treatm ent. 
Survival and side-effects were also described.
T h e  sample size calculation was based on the two-stage 
G e h a n ’s design aiming to include 9 patients and then includ­
ing additional patients according to the number of responses 
observed in the first stage. This guarantees that the probability 
of an active treatm ent (real response rate ^30% ) exhibiting 
no  responses in the first 9 patients (that is, false negative 
result) is 0.05 and allows the effectiveness of the trea tm ent 
regim en to be estimated with a standard error of 10% [11].
Survival curves and time to progression curves were esti­
m ated  using the K aplan-M eier technique [12].
Treatment
T h e  chem otherapy was given according to the following 
schedule: E  60 m g/m 2 i.v, on day 1. If  this dose was well 
to lerated , then the dose of E  was increased by 10 m g/m 2 in 
the following cycles to 80 mg/m2 as the maximum dose. P 
100 m g/m 2 diluted in 1 litre normal saline was adm inistered 
over a 4-h period with adequate pre- and posthydration. T h e  
cycle was repeated every 21 days. T h e  drug dose was modified 
for subsequent courses according to the degree of haem atolog- 
ical toxicity (Table 1).
I f  the  treatm ent had  to be postponed for more than  4 weeks* 
the response to treatm ent was evaluated and the patient went 
off study. T h e  dose of E was reduced by 50% in the presence 
of a bilirubin level of 35-50 mmol/1; no epirubicin was given if 
this level reached > 5 0  mmol/1.
A fter three cycles of EP* the patients were given irradiation 
therapy  as described by the Gastrointestinal T u m o r Study
Table 1. Dose attenuation schedule fo r  bone marrow depression
Leucocytes 
(x 109/l)
Thrombocytes 
(x 109/1) Epirubicin Cisplatin
> 4 > 100 100% 100%
3-4 75-100 75% 75%
< 3 < 7 5 Postpone 1 week
G roup [7] consisting of 40 Gy (split course) in com bination 
with 5 -F U  (500 m g/m 2) given as a bolus injection imm ediately 
prior to radiotherapy on days 1-3 of the two irradiation 
periods of 2 weeks each* with an interval of 2 weeks. After the 
irradiation* another three cycles o f  E P  were given if  after three 
cycles stable disease (SD) or a better response was achieved.
T h e  patients were evaluated for response after three cycles 
of chem otherapy and 4 weeks after six cycles. T h e  response 
was assessed by com puterised tom ography (C T ). T he  
response was defined according to W H O  guidelines for non- 
measurable disease [13]. A complete response (CR) was there­
fore defined as the complete disappearance o f all known 
disease. A  partial response (PR) was defined as an estimated 
decrease in tum our size o f ^ 5 0 % , and no change (N C) was 
defined as no significant change. T h e  latter included SD* an 
estimated decrease in  tum our size ^50% * an d  lesions w ith an 
estimated size increase of < 25% . Disease progression (PD ) 
was defined as the appearance o f a new lesion n o t previously 
identified or an estim ated increase of 2=25% in the size of 
existent lesions. A  confirmation after 4 weeks was required in 
case of C R  or PR. T he  duration  of response and  of survival 
were m easured from the start o f chem otherapy. Toxicity was 
assessed using a 0 -4  grading system according to the W H O
[13], T he R T O G /E O R T C  Late Radiation M orbidity  Scoring 
scheme was also used  for the small/large intestine* liver* kid­
ney* spinal cord and skin.
RESULTS
Between O ctober 1987 and January 1992* 61 patients with 
locally advanced disease were registered into the trial. Six 
patients d id  not fulfil the inclusion criteria: no measurable 
lesions for 2 patients* 1 had  an inadequate histology, 1 liver 
metastases* 1 had ascites and  1 also had  b reast cancer and  was 
treated w ith C M F. 2 o ther patients* although eligible* were 
excluded from  the analysis because they experienced digestive 
haem orrhage before the trea tm ent could start. Consequently, 
the results are based on the 53 eligible patients for whom  the 
treatm ent started. T h e  patient characteristics are given in 
Table 2. All 53 patients had  histological confirmation of 
adenocarcinom a o f the pancreas.
O f  the 53 eligible patients, 49 received th e  required initial 
three cycles of chem otherapy. O f  these 49 patients* 8 had 
progression and therefore were no t given any further treatm ent 
and 1 patien t refused further trea tm en t due  to persistent 
nausea and  vomiting. In addition to the rem ain ing  40 patients*
1 m ore patient* who received only two cycles o f chemotherapy* 
received radiotherapy because he was considered  unfit for 
further chemotherapy. O u t of these 41 patients who received 
radiotherapy* 37 com pleted the radio therapy split course while 
the otiier 4 patients received only the first part. 2 patients 
could no t tolerate any m ore treatm ent, 1 suffered a digestive 
haem orrhage and jaundice and the o ther had  progressive 
disease. A m ong the  37 patients who com pleted  the split
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Table 2, Patient characteristics
»=53
Age (years)
Median (range) 59 (37-70)
Sex
Male 34
Female 19
Weight loss (%)
None 8
ss 10 15
> 10 27
Unknown► 3
WHO performance status
0 22
1 29
2 2
Prior surgery
None 22
Palliative 31
course, 24 patients received further chemotherapy and 13 
patients did not receive any more chemotherapy: 8 patients 
had progression* 3 refused further treatment, and treatment 
was stopped for 2 patients due to toxicity, Treatment was 
stopped for 1 patient due to excessive toxicity after the fourth 
cycle of chemotherapy. 5 more patients had only five cycles: 2 
due to toxicity, 1 refused further treatment, 1 had a very poor 
digestive tolerance and 1 was lost to follow-up after the fifth 
cycle. 18 patients (34%) completed the additional three cycles 
of chemotherapy.
The response after the first three cycles of chemotherapy 
was 1 CR, 7 PR (CR + PR; 8/53, 15%; 95% Cl: 7-28%), 
36 SD and 6 PD (Table 3).
The response at the end o f the treatment was 3 CR, 11 PR* 
making an overall response rate of 26% (14/53* 95% CL 15- 
40%), 30 patients achieved SD. 7 patients had PD, of whom
1 patient had early progression. 1 patient had an early death 
due to septic shock during leucopenic period and 1 patient 
could not be evaluated after treatment.
At the time of the analysis, 3 patients were alivej 50 patients 
had died, 46 due to progressive disease* 2 due to toxicity of 
the chemotherapy, 1 because of pulmonary infection, 1 due to 
cerebral insufficiency.
The median duration o f survival of all treated patients was
50 All patients
JO
XIoW)ÛH
Months
Number of patients at risk: 
53 46 26 U 7 1 All
patients
Figure 1. Duration o f survival.
Table 4. Chemotherapy side-effects (n —53) (worst grade)
Side-effect 0 1 2 3 4 Pre-existing Unknown
WBC 50 2 0 1 0 0 0
Granulocytes 43 0 5 0 0 0 5
Platelets 26 13 6 2 6 0 0
Nausea/vomiting 1 5 15 30 2 0 0
Diarrhoea 26 12 12 1 0 2 0
Oral 45 5 3 0 0 0 0
Liver 46 4 1 0 1 0 1
Renal 40 8 3 1 0 0 1
Hair 9 2 10 30 0 1 1
Infection 38 S 3 2 1 0 1
Peripheral
neuropathy
46 4 2 0 0 0 1
10.8 months (range 7 days to 41.5 months. The 1-year 
survival was 49% (95% Cl: 35-63%) (Figure 1).
The median survival of responding patients was 15.1 and of 
patients with SD 10.3 months. The median time to pro­
gression was 8.9 months and the median duration of response
13.1 months.
Toxicity and side-effects of chemotherapy and irradiation 
are shown in Tables 4 and 5, respectively.
The chemotherapy was in general well tolerated. The grade
3 toxicity for nausea and vomiting is due to the WHO scoring
Table 3. Response to treatment Table 5. Side-effects due to chemo-irradiation (n = 41)
After 3 cycles Overall Sid e-effect 0 1 2 3 4 Unknown
Complete response 1 3 WBC 39 0 0 0 0 2
Partial response 7 11 Granulocytes 26 0 0 0 0 15
Stable disease 36 30 Platelets 26 6 5 2 0 2
Progression 6 6 Gastro-intestinal 8 19 8 5 1 0
Early progression 1 1 Small/large intestine 24 9 6 0 0 2
Early death due to septic shock 1 1 Liver 38 0 1 1 0 1
during leucopenic period Kidney 39 1 0 0 0 1
No evaluation during or after the 1 1 Spinal cord 41 0 0 0 0 0
treatment (two cycles) Skin 41 0 0 0 0 0
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system which indicates a 3 if anti-emetics are given prophylac- 
tically. In fact, most patients received anti-emetics by which 
the treatment was tolerable. The split course irradiation in 
combination with 5-FU was also generally well tolerated.
DISCUSSION
Treatment of locally advanced pancreatic cancer is at best 
palliative. The best approach seems to be a combination of 
systemic treatment with irradiation [8]. However* only one 
randomised trial has proven this [7]. According to data from 
the literature, a median survival between 8.4 and 14 months 
can be expected with the combined approach, whereas the 
median survival for untreated patients with locally advanced 
disease is between 3-5 months [8].
The aim of this study was to investigate the role of the 
addition of systemic treatment in the form of E and P to the 
known local treatment consisting of irradiation in combination 
with 5-fluorouracil. The treatment was moderately tolerated. 
The chemotherapy-related toxicity consisted mainly of myelo- 
suppression and the chemoradiotherapy-related toxicity of 
gastrointestinal side-effects. However, although according to 
WHO criteria the toxicity was mild, the long duration of 
the treatment period makes the complete treatment difficult 
to endure.
The results obtained in this study (median survival 10.8 
months) are not superior to the data obtained with the 
combined modality treatment published in the literature
[7]. Therefore, we conclude that the addition o f the sys­
temic treatment with E and P seems to offer no additional 
advantage and cannot be recommended, although simpler 
regimens of chemotherapy followed by irradiation (± 
chemotherapy) might be worth assessing, particularly 
because o f the potential advantage of identifying the initial 
chemotherapy responders.
T o place the results of this trial in proper perspective, it 
should be noted that this was a multicentre study and that 
there was no upper limit to the size of the tumour in patients 
treated in this study. Patients with tumours as great as
11 cm in diameter were included in the trial. It is likely that 
patients with such large tumours have distant metastases.
The combined modality approach is only worthwhile for 
localised disease. Therefore, the staging procedure in locally 
advanced disease should include a laparoscopic evaluation. 
Nearly half the patients with presumed resectable localised 
disease appear to have small but visible abdominal metastases 
during laparoscopy [14, 15]. In the non-resectable cases, this 
is probably even more.
From an experimental and theoretical point of view* it is of 
importance for future trials not to interrupt the cytostatic 
treatment period.
Another reason not to divide the treatment period is that 
only about half the patients could be treated according to the 
planned treatment schedule and could receive chemotherapy
after the irradiation. For most patients, the whole schedule is 
too difficult to endure and in addition, because most of the 
responses were documented after the first three cycles, it 
remains questionable whether the postirradiation courses of 
chemotherapy are of any use.
To improve the results of treatment of pancreatic cancer, it 
is of great importance to have more effective chemotherapy 
schedules. New drugs or better combination treatments are 
urgently needed.
An important question which should also be answered in 
the near future is: what is the best chemo-irradiation regi­
men? From the radiobiological point o f view, the split 
course irradiation is now considered outdated, but so far no 
irradiation schedule has been demonstrated to be superior.
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